487 related articles for article (PubMed ID: 31132795)
1. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
[TBL] [Abstract][Full Text] [Related]
2. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
[TBL] [Abstract][Full Text] [Related]
4. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
[TBL] [Abstract][Full Text] [Related]
5. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
[TBL] [Abstract][Full Text] [Related]
7. Lasmiditan in patients with common migraine comorbidities: a
Clemow DB; Baygani SK; Hauck PM; Hultman CB
Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
[TBL] [Abstract][Full Text] [Related]
8. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
[No Abstract] [Full Text] [Related]
9. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
[TBL] [Abstract][Full Text] [Related]
10. The Effect and Safety of 5-HT
Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
[TBL] [Abstract][Full Text] [Related]
11. Short-term efficacy and safety of lasmiditan, a novel 5-HT
Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
Maiti R; Mishra A; Puliappadamb HM; Jena M; Srinivasan A
J Clin Pharmacol; 2021 Dec; 61(12):1534-1544. PubMed ID: 34472095
[TBL] [Abstract][Full Text] [Related]
14. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
[TBL] [Abstract][Full Text] [Related]
15. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Loo LS; Ailani J; Schim J; Baygani S; Hundemer HP; Port M; Krege JH
J Headache Pain; 2019 Jul; 20(1):84. PubMed ID: 31340760
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
18. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
Kuca B; Silberstein SD; Wietecha L; Berg PH; Dozier G; Lipton RB;
Neurology; 2018 Dec; 91(24):e2222-e2232. PubMed ID: 30446595
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial.
Takeshima T; Komori M; Tanji Y; Ozeki A; Tatsuoka Y
Adv Ther; 2022 Nov; 39(11):5274-5288. PubMed ID: 36138260
[TBL] [Abstract][Full Text] [Related]
20. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
